Study of The Analgesic Profile of Two Adjuvants Added to Low Dose Hyperbaric Bupivacaine Versus One Adjuvant in Patients Undergoing Anal Surgery Using Spinal Anesthesia

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Spinal Anesthesia AdministrationAnalgesicAnorectal Surgery
Interventions
DRUG

Group F (fentanyl group)

Group F (fentanyl group):will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 0.5 ml (25 mcg) Fentanyl and 1 ml glucose 5% with total volume of 3ml.

DRUG

Group D :Dexmedetomidine group

Group D :Dexmedetomidine group: will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5% and 1 ml (4 mcg) Dexmedetomidine and 0.5 ml glucose 5% with total volume of 3ml.

DRUG

Group DF :Fentanyl and Dexmedetomidine group

Fentanyl and Dexmedetomidine group:will receive intrathecal 1.5 ml hyperbaric bupivacaine 0.5%, 0.5 ml (25 mcg) Fentanyl and 1 ml (4 mcg) Dexmedetomidine with total volume of 3ml.

Trial Locations (1)

Unknown

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT07114263 - Study of The Analgesic Profile of Two Adjuvants Added to Low Dose Hyperbaric Bupivacaine Versus One Adjuvant in Patients Undergoing Anal Surgery Using Spinal Anesthesia | Biotech Hunter | Biotech Hunter